Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XM01 versus placebo for chemotherapy-induced anaemia in patients with solid or non-myeloid haematological malignancies receiving non-platinum chemotherapy
ISRCTN08063129Phase 3Completed
- Sponsor
- BioGeneriX AG
- Start
- Nov 2005
- Modality
- Recombinant Proteins and Enzymes
01
Overview
A Phase 3 trial of epoetin theta in chemotherapy-induced anaemia (CIA), Nonhematologic neoplasms, hematopoietic malignancies, sponsored by BioGeneriX AG. Started Nov 2005; status: completed.
02
Drugs
epoetin theta
03
Conditions
chemotherapy-induced anaemia (CIA)Nonhematologic neoplasmshematopoietic malignancies
Beyond the preview
Go deeper on ISRCTN08063129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN08063129.